Virus safety of prothrombin complex concentrates and factor IX concentrates

Thrombosis Research

Volumn 95, Issue 4 SUPPL. 1, 1999, Pages

  Seitz, Rainer ^a   Dodt, Johannes ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

Coagulation factor concentrates; Regulatory framework; Virus safety

Indexed keywords

BLOOD CLOTTING FACTOR 9 CONCENTRATE; PROTHROMBIN COMPLEX;

BLOOD DONOR; DRUG LEGISLATION; DRUG QUALITY; DRUG SURVEILLANCE PROGRAM; GOOD MANUFACTURING PRACTICE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; VIRUS TRANSMISSION;

EID: 0032880763     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00080-8     Document Type: Article

References (15)

1. Schramm W. Chronologie zu Hämophilie und AIDS in den Hamburger Hämophilie-Symposien 1983-1993. 1994;Springer, Beril-Heidelberg-New York.
2. Nübling C.M., Chudy M., Löwer J. Virus testing of plasma pools and blood products by nucleic acid amplification. Hämostaseologie. 16:1996;274-276.
3. Council of Europe. Guide to the use, preparation and quality control of blood components. Recommendation No. R (95) 15. Third Edition, 1997.
4. Wissenschaftlicher Beirat der Bundesärztekammer und Paul-Ehrlich-Institut. Richtlinien zur Blutgruppenbestimmung und Bluttransfusion (Hämotherapie). Köln: Deuscher Ärzteverlag; 1996.
5. Glück D., Maurer C., Kubanek B. Infektionsmarker bei Blutspenden. Infusionsther Transfusionsmed. 24:1997;167-170.
6. Schreiber G.B., Busch M.P., Kleinman S.H. The risk of transfusion-transmitted viral infections. New Engl J Med. 334:1996;1685-1690.
7. Hilfenhaus J., Herrmann A., Mauler R., Prince A.M. Inactivation of the AIDS-causing retrovirus in antihemophilic plasma protein preparations by pasteurization. Vox Sang. 50:1986;208-211.
8. Horowitz B., Wiebe M.E., Lippin A., Stryker M.H. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion. 25:1985;516-522.
9. Horowitz B., Prince A.M., Hamman J., Watklevicz C. Viral safety of solvent/detergent treated blood products. Blood Coag Fibrinol. 5(Suppl 3):1994;S21-S28.
10. Centers of Disease Control. Morbidity and Mortality Weekly Report January 19, Vol. 45, 1996. p. 29-32.
11. Chudy M., Nübling C.M., Scheiblauer H., Willkommen H., Kurth R., Löwer J. Virusübertragungen durch Blutprodukte. Mögliche Ursachen und Konsequenzen Hämostaseologie. 15:1995;215-219.
12. Dichtelmüller H., Rudnick D., Breuer B. Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degree C. Biologicals. 24:1996;125-130.
13. Peerlink K., Arnout J., Di Giambattista M. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thrombos Haemostas. 77:1997;80-86.
14. Commission of the European Communities. Directive laying down the principles and guidelines of good manufacturing practice for medicinal products for human use. 91/356/EEC.
15. Commission of the European Communities, DG III. Annex to the EC guide to GMP: Manufacture of products derived from human blood and plasma. III/3232/92-EN.